Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qilu Jianshen Granule is a Traditional Chinese Medicine (TCM) hospital preparation developed by the Affiliated Yueyang Hospital of Integrated Traditional Chinese and Western Medicine at the Shanghai University of Traditional Chinese Medicine. It is specifically formulated to treat senile debilitating syndrome (geriatric frailty) and kidney qi deficiency syndrome in the elderly. The preparation is composed of several herbal ingredients, most notably *Astragalus membranaceus* (Huangqi) and *Cervus elaphus* (Deer antler), which are traditionally used to tonify the kidney, replenish essence, and strengthen the spleen. Its mechanism of action involves the modulation of systemic inflammatory markers and the improvement of metabolic and endocrine functions, which collectively aim to enhance muscle strength, physical performance, and overall vitality in the elderly population.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qilu Jianshen Granule.